الصفحة الرئيسية>>EM574

EM574 (Synonyms: Idremcinal)

رقم الكتالوجGC45446

EM574 هو ناهض قوي لمستقبلات موتيلين في غار المعدة البشري والجهاز الهضمي للأرانب في المختبر

Products are for research use only. Not for human use. We do not sell to patients.

EM574 التركيب الكيميائي

Cas No.: 110480-13-2

الحجم السعر المخزون الكميّة
500μg
188٫00
متوفر
1mg
358٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

EM574 is a motilin receptor agonist with an IC50 value of 6.17 nM for binding to rabbit gastric antral smooth muscle homogenates in a radioligand binding assay.1 It also binds to human smooth muscle homogenates in a radioligand binding assay (Kd = 7.8 nM).2 EM574 induces contraction of isolated rabbit, but not rat or guinea pig, intestine (EC50 = 5.5 nM).1 It increases antral motility and enhances gastric emptying in canine models of gastroparesis when administered intraduodenally at a dose of 0.03 mg/kg following a semi-solid meal.3

References
1. Sato, F., Sekiguchi, M., Marui, S., et al. EM574, an erythromycin derivative, is a motilin receptor agonist in the rabbit. Eur. J. Pharmacol. 322(1), 63-71 (1997).
2. Satoh, M., Sakai, T., Fujikura, K., et al. EM574, an erythromycin derivative, is a potent motilin receptor agonist in human gastric antrum. J. Pharmacol. Exp. Ther. 271(1), 574-579 (1994).
3. Sato, F., Marui, S., Inatomi, N., et al. EM574, an erythromycin derivative, improves delayed gastric emptying of semi-solid meals in conscious dogs. Eur. J. Pharmacol. 395(2), 165-172 (2000).

مراجعات

Review for EM574

Average Rating: 5 ★★★★★ (Based on Reviews and 16 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for EM574

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.